Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Company Profile and bullboard matches:

V.AEP , SCIA , UNIR
Sort by: Date|Relevance

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. Clinical-stage biopharmaceutical company Fate Thera...

Construction Pipeline Shows Undervalued Opportunity

This Vancouver Construction Company Continues to Trade Undervalued with a Long List of Projects in the Pipeline. A Vancouver-based general contracting company, with a list of international jobs in the pipeline, is trading for just eight cents apiece right now. From ea...

SunPower's Energy Storage Reflecting Well on Its Shares

SunPower Corp. shares are trading 6% higher today as the firm announced that its Equinox Storage paired with its platform provides energy independence to residential users. Global sustainable energy company SunPower Corp. (SPWR:NASDAQ) today announced the introduc...

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%

Pulmatrix's shares opened 90% higher today after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. Prior to the U.S. markets open this morning on the first day of trading in 2020, clinical...

NGM Biopharma Shares Rise on Positive Topline Data from Phase 2 NASH Trial

Shares of NGM Biopharmaceuticals reached a new 52-week intraday high price after the company posted positive topline data from Cohort 4 of its Phase 2 study of aldafermin in NASH Patients. On a day when world financial markets traded lower across the board, ...

Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. Novavax Inc. (NVAX:NASDAQ) , which focuses its efforts on developing next-generation vaccines to address infectious diseases, ye...

Buzz on the Bullboards: Summer's most talked about stocks

August has been a rough month for North American stock markets, with red days and a lot of flat trading activity. Shares of U.S. banks fell this week after several regional lenders were hit with a credit downgrade. Retailers are stuck with products that aren&CloseCurl...

Shaping the Future of Medicine by Delivering Regenerative Medicines

(Click image to play video) Envision a chest pain that feels like the most severe form of heartburn you ever experienced before. This is one of the main symptoms of ischemia – a disease which millions of people around the globe live with every day. Treati...

dynaCERT Embarking on Tokenization of Carbon Credit Market

A first-generation end-to-end carbon credit marketplace tokenization system appears now under development leveraging dynaCERT’s unique patented and proven technology. Newly appointed FinTech pioneer to dynaCERT’s Advisory Board stated, “ Digiti...

Buzz on the Bullboards: In the COVID Fallout, New Players Emerge

Back in early March 2020, the COVID-19 pandemic was still not much of a concern for the markets. While investors were keeping an eye on it, compared to other geopolitical factors at the time, it was mostly an afterthought of little consequence. Fast-forward a year...
1 2 3